Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federica Morandi

Showing results (71-80 of 79) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 79 results.
Scientific Reports|November 21, 2023
Preclinical evidence for the effective use of TL-895, a highly selective and potent second-generation BTK inhibitor, for the treatment of B-cell malignanciesSamantha M Goodstal, Jing Lin, Timothy Crandall, et al.
Chemmedchem|December 7, 2018
Discovery of Affinity-Based Probes for Btk Occupancy AssaysHui Qiu, Richard Caldwell, Lesley Liu-Bujalski, et al.
Clinical Immunology (Orlando, Fla.)|January 29, 2016
Btk inhibition treats TLR7/IFN driven murine lupusAndrew T Bender, Albertina Pereira, Kai Fu, et al.
Bioorganic & Medicinal Chemistry Letters|September 24, 2018
Optimization of the efflux ratio and permeability of covalent irreversible BTK inhibitorsHui Qiu, Lesley Liu-Bujalski, Richard D Caldwell, et al.
Chemmedchem|September 28, 2021
Discovery of Covalent Bruton's Tyrosine Kinase Inhibitors with Decreased CYP2C8 Inhibitory ActivityHui Qiu, Zahid Ali, Julian Bowlan, et al.
Journal of Medicinal Chemistry|November 1, 2019
Discovery of BAY-298 and BAY-899: Tetrahydro-1,6-naphthyridine-Based, Potent, and Selective Antagonists of the Luteinizing Hormone Receptor Which Reduce Sex Hormone Levels in VivoLars Wortmann, Bernhard Lindenthal, Peter Muhn, et al.
Bioorganic & Medicinal Chemistry|May 1, 2021
Discovery of potent and selective reversible Bruton's tyrosine kinase inhibitorsHui Qiu, Zahid Ali, Andrew Bender, et al.
Journal of Medicinal Chemistry|December 13, 2023
Discovery of Orally Available and Brain Penetrant AEP InhibitorsDaniela Krummenacher, Weiping He, Bernd Kuhn, et al.
Journal of Medicinal Chemistry|August 2, 2019
Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological DiseasesRichard D Caldwell, Hui Qiu, Ben C Askew, et al.
Pageof 8

Showing results (71-80 of 79) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
Scientific Reports|November 21, 2023
Preclinical evidence for the effective use of TL-895, a highly selective and potent second-generation BTK inhibitor, for the treatment of B-cell malignanciesSamantha M Goodstal, Jing Lin, Timothy Crandall, et al.
Chemmedchem|December 7, 2018
Discovery of Affinity-Based Probes for Btk Occupancy AssaysHui Qiu, Richard Caldwell, Lesley Liu-Bujalski, et al.
Clinical Immunology (Orlando, Fla.)|January 29, 2016
Btk inhibition treats TLR7/IFN driven murine lupusAndrew T Bender, Albertina Pereira, Kai Fu, et al.
Bioorganic & Medicinal Chemistry Letters|September 24, 2018
Optimization of the efflux ratio and permeability of covalent irreversible BTK inhibitorsHui Qiu, Lesley Liu-Bujalski, Richard D Caldwell, et al.
Chemmedchem|September 28, 2021
Discovery of Covalent Bruton's Tyrosine Kinase Inhibitors with Decreased CYP2C8 Inhibitory ActivityHui Qiu, Zahid Ali, Julian Bowlan, et al.
Journal of Medicinal Chemistry|November 1, 2019
Discovery of BAY-298 and BAY-899: Tetrahydro-1,6-naphthyridine-Based, Potent, and Selective Antagonists of the Luteinizing Hormone Receptor Which Reduce Sex Hormone Levels in VivoLars Wortmann, Bernhard Lindenthal, Peter Muhn, et al.
Bioorganic & Medicinal Chemistry|May 1, 2021
Discovery of potent and selective reversible Bruton's tyrosine kinase inhibitorsHui Qiu, Zahid Ali, Andrew Bender, et al.
Journal of Medicinal Chemistry|December 13, 2023
Discovery of Orally Available and Brain Penetrant AEP InhibitorsDaniela Krummenacher, Weiping He, Bernd Kuhn, et al.
Journal of Medicinal Chemistry|August 2, 2019
Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological DiseasesRichard D Caldwell, Hui Qiu, Ben C Askew, et al.
Pageof 8